Newland Pharmaceutical Co., Ltd. (SHE:301277)

Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	334.4	281.58	270.02	51.13	34.21	36.45
Trading Asset Securities	453.13	525.16	589.5	701.36	8.67	-
Cash & Short-Term Investments	787.53	806.75	859.52	752.49	42.88	36.45
Cash Growth	-8.49%	-6.14%	14.22%	1654.94%	17.63%	-34.12%
Accounts Receivable	324.8	332.61	240.9	360.46	269.6	179.29
Other Receivables	0.61	0.24	0.19	0.26	0.16	0.3
Receivables	325.41	332.85	241.09	360.72	269.76	179.6
Inventory	31.35	45.06	31	53.52	78.57	49.42
Prepaid Expenses	-	-	-	-	-	1.25
Other Current Assets	10.13	10.37	25.04	20.38	9.8	1.78
Total Current Assets	1,154	1,195	1,157	1,187	401	268.49
Property, Plant & Equipment	616.16	574.78	388.2	295.52	225.67	210.5
Other Intangible Assets	36.5	36.82	38.08	38.77	39.71	39.9
Long-Term Deferred Tax Assets	-	-	-	-	1.01	0.83
Long-Term Deferred Charges	2.83	3.38	5.61	1.29	-	-
Other Long-Term Assets	37.01	3.73	20.96	11.08	0.51	2.23
Total Assets	1,847	1,814	1,610	1,534	667.9	521.96
Accounts Payable	100.43	138.66	87.75	106.37	80.26	43.5
Accrued Expenses	14.51	23.78	30.33	18.18	27.81	23.56
Short-Term Debt	0.86	0.73	-	-	91.33	90.12
Current Portion of Long-Term Debt	-	-	-	-	4.66	-
Current Portion of Leases	-	-	1.99	2.84	-	-
Current Income Taxes Payable	8.12	-	-	-	3.05	4.26
Current Unearned Revenue	2.05	5.32	4.43	4.61	1.68	0.41
Other Current Liabilities	62.73	48.3	14.96	24.01	11.8	15.89
Total Current Liabilities	188.7	216.78	139.47	156.01	220.58	177.73
Long-Term Debt	-	-	-	-	30.39	20.02
Long-Term Leases	4.13	2.25	0.73	2.88	-	-
Long-Term Unearned Revenue	41.82	41.88	10.04	10.3	10.56	10.81
Long-Term Deferred Tax Liabilities	11.88	9.77	9.78	5.39	-	-
Total Liabilities	246.53	270.69	160.02	174.58	261.53	208.57
Common Stock	280.06	280.06	200.04	133.36	100	100
Additional Paid-In Capital	644.77	644.77	724.78	791.46	5.49	1.78
Retained Earnings	667.27	610.7	517.09	424.79	292.48	207.5
Comprehensive Income & Other	7.48	6.67	6.11	6.33	4.56	4.11
Total Common Equity	1,600	1,542	1,448	1,356	402.53	313.39
Minority Interest	0.8	0.85	1.47	3.25	3.85	-
Shareholders' Equity	1,600	1,543	1,449	1,359	406.38	313.39
Total Liabilities & Equity	1,847	1,814	1,610	1,534	667.9	521.96
Total Debt	4.99	2.98	2.72	5.72	126.38	110.14
Net Cash (Debt)	782.55	803.77	856.8	746.77	-83.5	-73.69
Net Cash Growth	-8.82%	-6.19%	14.73%	-	-	-
Net Cash Per Share	1.99	2.05	2.19	2.48	-0.28	-0.25
Filing Date Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Total Common Shares Outstanding	392.08	392.08	392.08	392.08	294	294
Working Capital	965.72	978.24	1,017	1,031	180.43	90.76
Book Value Per Share	4.08	3.93	3.69	3.46	1.37	1.07
Tangible Book Value	1,563	1,505	1,410	1,317	362.82	273.49
Tangible Book Value Per Share	3.99	3.84	3.60	3.36	1.23	0.93
Buildings	-	211.94	169.21	151.69	148.36	128.24
Machinery	-	295.69	235.66	187.31	125.82	115.55
Construction In Progress	-	222.1	106.7	55.35	33.02	32.52

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.